Medtronic Breaks $104 Pivot, Aims for $118–$124 Targets After Reversal
Medtronic’s stock completed a Head & Shoulders reversal, breaking above the $104 pivot and targeting $118–$124 based on the pattern’s dollar range and bullish analyst outlooks. In Q3 Medtronic posted $9 billion revenue with 6% organic growth and $1.36 adjusted EPS, and reaffirmed 5.5% revenue growth for the year.
1. Technical Breakout and Price Targets
Medtronic’s stock formed a Head & Shoulders reversal, breaking above the $104 baseline pivot. Technical targets project a movement equal to the pattern’s dollar range as a baseline case, implying a move to $118, while a percentage-based bull case extends the target to $124.
2. Q3 Financial Results
In its latest quarter Medtronic reported $9 billion in revenue, driven by 6% organic growth plus foreign exchange tailwinds. The Cardiovascular segment led with nearly 14% growth (10.6% organically), followed by Diabetes at 8.3%, Medical Surgical at 2.7% and Neurosciences at 2.5%, with adjusted EPS of $1.36 and a 24.1% operating margin.
3. Reaffirmed Guidance and Capital Return
Management reaffirmed full-year revenue growth at 5.5% and adjusted EPS of $5.64, both near consensus estimates. The dividend yield stands at roughly 2.8% with a 50% payout ratio, supported by ongoing share repurchases aimed at continued capital return and a path toward Dividend King status.
4. Growth Catalysts and Valuation Upside
Upcoming catalysts include the Symplicity Spyral RDN system, Hugo robotic approvals and potential operational changes driven by Elliott activism. Trading at 17X forward earnings, Medtronic could see a multiple expansion toward the 22X peer average, suggesting a price near $125.